24 Roy Street
Seattle, WA 98109
Complete this contact form for media, investor relations and partnership/business development inquiries
Please leave this field empty.
* required fields
A Feasibility Study of the EMulate Therapeutics Voyager System in Patients with Recurrent Glioblastoma Multiforme (rGBM). This study is currently recruiting qualified patients.
Abstract presented by Xavier Figueroa, PhD, at Society for Neuro-Oncology 2016 Annual Conference, Scottsdale, AZ on November 19, 2016.
The latest information on publications highlighting EMulate Therapeutics research and advancements.
December 30, 2020
A Medical Technology That Has The Highest Potential Over Any We Follow
December 18, 2020
Hapbee Commences Trading on the Frankfurt Exchange Under the Symbol "HA1"
December 17, 2020
Hapbee Announces Additions to Advisory Board
EMulate Therapeutics Voyager® ulRFE® System for rGBM is an investigational medical device. Limited by United States law to investigational use only.
© EMulate Therapeutics 2021. All rights reserved.